Daunorubicin is an anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia. A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Mechanism
- Curator reviewed
Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
- Primary indication
- For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.Curator reviewed · 9 structured indications
- Formula / weight
- C27H29NO10 · 527.5199 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1996 · European Union, 2020
- Also known as
- Acetyladriamycin · Daunomycin · Daunorubicin liposomal · Leukaemomycin C · Rubidomycin
- Code names
- DNR · FI-6339 · NSC 82151 · RCRA Waste No. U059 · RP-13057
- Brand names
Resolves to
STQGQHZAVUOBTE-VGBVRHCVSA-NSMILESCOC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Daunorubicin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account